F. Hirayama

K. Motoyama, F. Hirayama, K. Uekama, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Effect of 2-Hydroxypropyl-β-cyclodextrin on Crystallization and Polymorphic Transition of Nifedipine in Solid State

Zheng Wang, F. Hirayama, K. Uekama, 1994, Pharmaceutical Research.

Erratum: "Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of tacrolimus" (The Journal of Pharmacology and Experimental Therapeutics (2001) 297 (547-555))

F. Hirayama, K. Uekama, H. Arima, 2001 .

Effects of chitosan on oxidative stress and related factors in hemodialysis patients.

F. Hirayama, K. Uekama, M. Otagiri, 2014, Carbohydrate polymers.

Polypseudorotaxane-based supramolecular hydrogels consisting of cyclodextrins and Pluronics as stabilizing agents for antibody drugs.

T. Higashi, K. Motoyama, F. Hirayama, 2020, Carbohydrate polymers.

Potential Use of Dendrimer/α-Cyclodextrin Conjugate as a Novel Carrier for Small Interfering RNA (siRNA)

F. Hirayama, K. Uekama, H. Arima, 2006 .

Potential Use of /2-Hydroxypropyl-β-cyclodextrin Nanoparticles as a New Photosensitizer in the Treatment of Cancer

A. Altaf, F. Hirayama, K. Uekama, 2014 .

Evaluation of photodynamic activity of C60/2-hydroxypropyl-β-cyclodextrin nanoparticles.

K. Motoyama, F. Hirayama, K. Uekama, 2012, Journal of pharmaceutical sciences.

Methods of Investigating and Preparing Inclusion Compounds

F. Hirayama, K. Uekama, 1990 .

Improvement of dissolution and suppository release characteristics of flurbiprofen by inclusion complexation with heptakis(2,6-di-O-methyl)-beta-cyclodextrin.

T. Imai, F. Hirayama, K. Uekama, 1985, Journal of pharmaceutical sciences.

Inhibitory Effects of Novel Hydrophilic Cyclodextrin Derivatives on Nitric Oxide Production in Macrophages Stimulated with Lipopolysaccharide

K. Motoyama, F. Hirayama, K. Uekama, 2001, Pharmaceutical Research.

Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.

K. Motoyama, F. Hirayama, K. Uekama, 2011, International journal of pharmaceutics.

Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated beta-cyclodextrins.

K. Motoyama, F. Hirayama, K. Uekama, 2009, Biological & pharmaceutical bulletin.

Effect of 2,6-di-O-methyl-alpha-cyclodextrin on hemolysis and morphological change in rabbit's red blood cells.

K. Motoyama, F. Hirayama, K. Uekama, 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Protective effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced hemolysis in vitro.

S. Tajiri, F. Hirayama, K. Uekama, 2002, Journal of pharmaceutical sciences.

In vitro and in vivo gene transfer by an optimized alpha-cyclodextrin conjugate with polyamidoamine dendrimer.

F. Hirayama, K. Uekama, H. Arima, 2003, Bioconjugate chemistry.

Antioxidant activities of chitosans and its derivatives in in vitro and in vivo studies.

F. Hirayama, K. Uekama, M. Otagiri, 2018, Carbohydrate polymers.

N-acetyl-L-methionine is a superior protectant of human serum albumin against post-translational oxidation as compared to N-acetyl-L-tryptophan

F. Hirayama, M. Otagiri, T. Maruyama, 2016, Biochemistry and biophysics reports.

O-carboxymethyl-O-ethylcyclomaltoheptaose as a delayed-release-type drug carrier: improvement of the oral bioavailability of diltiazem in the dog.

F. Hirayama, K. Uekama, T. Irie, 1989, Carbohydrate research.

Formation of stable hydrophilic C60 nanoparticles by 2-hydroxypropyl-β-cyclodextrin.

F. Hirayama, K. Uekama, K. Higashi, 2011, Molecular pharmaceutics.

Future aspects of biomedical applications of chitin and chitosan in diseases associated with oxidative stress

S. Ifuku, F. Hirayama, M. Otagiri, 2020 .

Surface-deacetylated chitin nanofibers reinforced with a sulfobutyl ether β-cyclodextrin gel loaded with prednisolone as potential therapy for inflammatory bowel disease.

S. Ifuku, F. Hirayama, K. Uekama, 2017, Carbohydrate polymers.

In vitro gene delivery mediated by lactosylated dendrimer (generation 3, G3)/α-cyclodextrin conjugates into hepatocytes

H. Jono, K. Motoyama, F. Hirayama, 2011 .

Preparation and evaluation of polyamidoamine dendrimer (G2)/branched-β-cyclodextrin conjugate as a novel gene transfer carrier

T. Anno, T. Higashi, K. Motoyama, 2011 .

Serum-resistant Gene Transfer Activity of Mannosylated Dendrimer/α-Cyclodextrin Conjugate (G3)

F. Hirayama, K. Uekama, H. Arima, 2006 .

Enhancement of gene transfer activity mediated by mannosylated dendrimer/alpha-cyclodextrin conjugate (generation 3, G3).

F. Hirayama, K. Uekama, H. Arima, 2006, Journal of controlled release : official journal of the Controlled Release Society.

Determination of the Stability Constants for Inclusion Complexes of Cyclodextrins with Various Drug Molecules by High Performance Liquid Chromatography

F. Hirayama, K. Uekama, T. Irie, 1978 .

Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA).

Hidetoshi Arima, F. Hirayama, K. Uekama, 2007, Journal of controlled release : official journal of the Controlled Release Society.

Involvement of CD14 in the inhibitory effects of dimethyl‐α‐cyclodextrin on lipopolysaccharide signaling in macrophages

K. Miyake, K. Motoyama, F. Hirayama, 2005, FEBS letters.

Preparation of hydrophilic C60(OH)10/2-hydroxypropyl-β-cyclodextrin nanoparticles for the treatment of a liver injury induced by an overdose of acetaminophen.

F. Hirayama, K. Uekama, T. Irie, 2015, Biomaterials.

Recent Aspect of Cyclodextrin-Based Drug Delivery System

F. Hirayama, K. Uekama, H. Arima, 2006 .

Hydrophobically Modified Polymer/α-Cyclodextrin Thermoresponsive Hydrogels for Use in Ocular Drug Delivery.

F. Hirayama, K. Uekama, M. Anraku, 2017, Molecular pharmaceutics.

Antioxidant and renoprotective activity of 2‐hydroxypropyl‐β‐cyclodextrin in nephrectomized rats

F. Hirayama, K. Uekama, M. Otagiri, 2016, The Journal of pharmacy and pharmacology.

Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration.

F. Hirayama, K. Uekama, K. Minami, 1998, Journal of pharmaceutical sciences.

6A-O-[(4-Biphenylyl)acetyl]-α-, -β-, and -γ-cyclodextrins and 6A-deoxy-6A-[[(4-biphenylyl)acetyl]amino] -α-, -β-, and -γ-cyclodextrins : Potential prodrugs for colon-specific delivery

F. Hirayama, K. Uekama, K. Minami, 1997 .

Potential use of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo

T. Anno, T. Higashi, K. Motoyama, 2012, Journal of drug targeting.

Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with α-cyclodextrin as DNA carriers to tumor cells

T. Higashi, K. Motoyama, F. Hirayama, 2012, Cancer Gene Therapy.

Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with alpha-cyclodextrin.

F. Hirayama, K. Uekama, H. Arima, 2002, Bioconjugate chemistry.

Acid-catalyzed hydrolysis of maltosyl-β-cyclodextrin

F. Hirayama, K. Uekama, Masanobu Yamamoto, 1992 .

Peracylated β‐Cyclodextrins as Novel Sustained‐release Carriers for a Water‐soluble Drug, Molsidomine

F. Hirayama, K. Uekama, T. Horikawa, 1994, The Journal of pharmacy and pharmacology.

X-RAY CRYSTALLOGRAPHIC DETERMINATION OF THE ABSOLUTE CONFIGURATION OF (+) FLURBIPROFEN UTILIZING β-CYCLODEXTRIN COMPLEXATION

K. Harata, T. Imai, F. Hirayama, 1984 .

The Structure of the Cyclodextrin Complex. XVI. Crystal Structure of Heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin-p-Iodophenol (1 : 1) Complex Tetrahydrate

K. Harata, F. Hirayama, K. Uekama, 1983 .

The Structure of the Cyclodextrin Complex. X. Crystal Structure of α-Cyclodextrin-Benzaldehyde (1 : 1) Complex Hexahyderate

K. Harata, F. Hirayama, K. Uekama, 1981 .

Release characteristics of a short-chain fatty acid, n-butyric acid, from its beta-cyclodextrin ester conjugate in rat biological media.

F. Hirayama, K. Uekama, H. Arima, 2000, Journal of pharmaceutical sciences.

Inhibitory Effects of 2,6-Di-O-methyl-3-O-acetyl-β-cyclodextrins with Various Degrees of Substitution of Acetyl Group on Macrophage Activation and Endotoxin Shock Induced by Lipopolysaccharide

K. Motoyama, F. Hirayama, K. Uekama, 2006 .

Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin.

T. Anno, T. Higashi, K. Motoyama, 2012, International journal of pharmaceutics.

Determination of stability constant of beta-cyclodextrin complexes using the membrane permeation technique and the permeation behavior of drug-competing agent-beta-cyclodextrin ternary systems.

F. Hirayama, K. Uekama, H. Arima, 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Inhibitory effects of dimethylacetyl-beta-cyclodextrin on lipopolysaccharide-induced macrophage activation and endotoxin shock in mice.

A. Matsukawa, K. Motoyama, F. Hirayama, 2005, Biochemical pharmacology.

A moderate interaction of maltosyl-alpha-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin.

F. Hirayama, K. Uekama, H. Arima, 2001, Biological & pharmaceutical bulletin.

PREPARATION AND PHARMACEUTICAL EVALUATION OF

F. Hirayama, K. Uekama, S. Mieda, 1999 .

Preparation and Pharmaceutical Evaluation of Heptakis(2,6-Di-o-Methyl-3-o-Acetyl)-ß-Cyclodextrin

F. Hirayama, K. Uekama, S. Mieda, 1999 .

Improvement of gene delivery mediated by mannosylated dendrimer/alpha-cyclodextrin conjugates.

F. Hirayama, K. Uekama, H. Arima, 2005, Journal of controlled release : official journal of the Controlled Release Society.

Physiologically Stable Hydrophilic C60 Nanoparticles for Photodynamic Therapy

F. Hirayama, K. Uekama, M. Anraku, 2019, ACS Applied Nano Materials.

Prolonged Retention of Doxorubicin in Tumor Cells by Encapsulation of γ-Cyclodextrin Complex in Pegylated Liposomes

F. Hirayama, K. Uekama, H. Arima, 2006 .

Enhancement of antitumor effect of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes

F. Hirayama, K. Uekama, H. Arima, 2006, Journal of drug targeting.

Stoichiometry-dependent photodimerization of tranilast in a γ-cyclodextrin inclusion complex

F. Hirayama, K. Uekama, T. Utsuki, 1991 .

Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins.

K. Motoyama, F. Hirayama, K. Uekama, 2011, International journal of pharmaceutics.

N-acetyl-l-methionine is a superior protectant of human serum albumin against photo-oxidation and reactive oxygen species compared to N-acetyl-L-tryptophan.

F. Hirayama, M. Otagiri, T. Maruyama, 2014, Biochimica et biophysica acta.

Preparation and pharmaceutical evaluation of liposomes entrapping salicylic acid/gamma-cyclodextrin conjugate.

F. Hirayama, K. Uekama, H. Arima, 2006, Chemical & pharmaceutical bulletin.

Crystal structure of heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin complexes with m-iodophenol and 4-biphenylacetic acid. Guest-induced conformational change of a pyranose ring

K. Harata, F. Hirayama, K. Uekama, 1992 .

Crystal structures of heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin complexes with (R)- and (S)-Flurbiprofen

K. Harata, T. Imai, F. Hirayama, 1988 .

Crystal structures of permethylated .BETA.-cyclodextrin complexes with R-(-)- and S-(+)-flurbiprofen.

K. Harata, T. Imai, F. Hirayama, 1984 .

Crystal structures of cyclodextrin complexes with chiral molecules

K. Harata, F. Hirayama, M. Otagiri, 1984 .

Slow-release characteristics of diltiazem from ethylated beta-cyclodextrin complexes.

F. Hirayama, K. Uekama, Y. Horiuchi, 1990, Journal of pharmaceutical sciences.

Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.

F. Hirayama, K. Uekama, K. Miyake, 1999, Journal of pharmaceutical sciences.

Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration.

F. Hirayama, K. Uekama, H. Arima, 2002, Journal of controlled release : official journal of the Controlled Release Society.

Preparation of prednisolone‐appended α‐, β‐ and γ‐cyclodextrins: Substitution at secondary hydroxyl groups and in vitro hydrolysis behavior

F. Hirayama, K. Uekama, H. Arima, 2001 .

6A-O-[(4-biphenylyl)acetyl]-alpha-, -beta-, and -gamma-cyclodextrins and 6A-deoxy-6A-[[(4-biphenylyl)acetyl]amino]-alpha-, -beta-, and -gamma-cyclodextrins: potential prodrugs for colon-specific delivery.

F. Hirayama, K. Uekama, K. Minami, 1997, Journal of medicinal chemistry.

In‐vitro Evaluation of Biphenylyl Acetic Acid‐β‐Cyclodextrin Conjugates as Colon‐targeting Prodrugs: Drug Release Behaviour in Rat Biological Media

F. Hirayama, K. Uekama, K. Minami, 1996, The Journal of pharmacy and pharmacology.

Conformational Versatility of Open-Chain Polyethers: Crystal and Molecular Structures of the Ba(SCN)2 Complexes of Two Heptaethyleneglycol Diaryl Ethers†

G. Sheldrick, R. Hilgenfeld, W. Saenger, 1984 .

Analysis of the Vibrational Structure in Induced Circular Dichroism of Chlorobenzene Included in β-Cyclodextrin

F. Hirayama, K. Uekama, H. Yamaguchi, 1978 .

Synthesis of 10-Arylpyrimido [4, 5-b] quinoline-2, 4 (3H, 10H) diones (10-Aryl-5-deazaflavins) and Their Use in Oxidations of Alcohols and Amines

K. Shinozuka, F. Hirayama, K. Uekama, 1980 .

The Structure of the Cyclodextrin Complex. XIX. Crystal Structures of Hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin Complexes with (S)- and (R)-Mandelic Acid. Chiral Recognition through the Induced-Fit Conformational Change of the Macrocyclic Ring

K. Harata, F. Hirayama, K. Uekama, 1987 .

Cyclodextrin-Induced Change in Crystal Habit of Acetylsalicylic Acid in Aqueous Solution

K. Motoyama, F. Hirayama, K. Uekama, 2012 .

Conformation of permethylated cyclodextrins and the host-guest geometry of their inclusion complexes

K. Harata, F. Hirayama, K. Uekama, 1984 .

Stoichiometry-dependent changes of solubility and photoreactivity of an antiulcer agent, 2′-carboxymethoxy-4,4′-bis(3-methyl-2-butenyloxy) chalcone, in cyclodextrin inclusion complexes

F. Hirayama, K. Uekama, T. Utsuki, 1993 .

5-Fluorouracil acetic acid/beta-cyclodextrin conjugates: drug release behavior in enzymatic and rat cecal media.

K. Motoyama, F. Hirayama, K. Uekama, 2010, International journal of pharmaceutics.

Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats.

F. Hirayama, K. Uekama, H. Arima, 2002, Journal of controlled release : official journal of the Controlled Release Society.

Crystal structures of permethylated -cyclodextrin complexes with L- and D-mandelic acids

K. Harata, F. Hirayama, K. Uekama, 1984 .

Fluorescence Behavior of 7-Substituted Coumarin Derivatives by Inclusion Complexation with β-Cyclodextrin

F. Hirayama, K. Uekama, M. Otagiri, 1983 .

The Structure of the Cyclodextrin Complex. XV. Crystal Structure of Hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin–p-Nitrophenol (1 : 1) Complex Monohydrate

K. Harata, F. Hirayama, K. Uekama, 1982 .

The structure of the Cyclodextrin Complex. XIV. Crystal Structure of Hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin–Benzaldehyde (1 : 1) Complex

K. Harata, F. Hirayama, K. Uekama, 1982 .

The Structure of the Cyclodextrin Complex. XI. Crystal Structure of Hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin–p-Iodoaniline Monohydrate

K. Harata, F. Hirayama, K. Uekama, 1982 .

Inclusi on complexations of steroid hormones with cyclodextrins in water and in solid phase

Masaki Yamasaki, F. Hirayama, K. Uekama, 1982 .

MODIFICATION OF SUBSTITUENT EFFECT BY CYCLODEXTRIN COMPLEXATION IN ALKALINE HYDROLYSIS OF 7-SUBSTITUTED COUMARINS

F. Hirayama, K. Uekama, M. Otagiri, 1981 .

Inclusion Complexation of Prostaglandin F2α with α-and β-Cyclodextrins in Aqueous Solution

F. Hirayama, K. Uekama, 1978 .

Improvements of dissolution characteristics and chemical stability of 16,16-dimethyl-trans-delta 2-prostaglandin E1 methyl ester by cyclodextrin complexation.

F. Hirayama, K. Uekama, K. Ikeda, 1979, Journal of pharmaceutical sciences.

[Inclusion complexation of p-hydroxybenzoic acid esters with alpha- and beta-cyclodextrins: dissolution behaviors and antimicrobial activities (author's transl)].

F. Hirayama, K. Uekama, M. Otagiri, 1980, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

The Structure of the Cyclodextrin Complex. XVIII. Crystal Structure of β-Cyclodextrin–Benzyl Alcohol (1:1) Complex Pentahydrate

K. Harata, F. Hirayama, K. Uekama, 1985 .

Model Analysis for Oral Absorption of a Drug/Cyclodextrin Complex Involving Competitive Inclusion Complexes

F. Hirayama, K. Uekama, H. Arima, 2002 .

Inhibitory effect of guest molecules on acid-catalysed ring-opening of β-cyclodextrin

F. Hirayama, K. Uekama, T. Utsuki, 1993 .

Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation.

F. Hirayama, K. Uekama, M. Otagiri, 1983, Journal of pharmaceutical sciences.

Inclusion Complexation of β-Cyclodextrin with Some Sulfonamides in Aqueous Solution

F. Hirayama, K. Uekama, M. Otagiri, 1978 .

CRYSTAL AND MOLECULAR STRUCTURE OF 2 : 2 (±) FLURBIPROFEN-β-CYCLODEXTRIN COMPLEX

K. Harata, T. Imai, F. Hirayama, 1983 .

Crystal Structures of β-Cyclodextrin and Heptakis(2,6-di-O-methyl)-β-cyclodextrin Complexes with Carmofur

G. Tsoucaris, K. Harata, F. Hirayama, 1988 .

EFFECTS OF α- AND β-CYCLODEXTRINS ON BASE-CATALYZED ISOMERIZATION OF PROSTAGLANDIN A1 AND PROSTAGLANDIN A2

F. Hirayama, K. Uekama, Masanori Daiguji, 1978 .

Inclusion Complexation of a Seleno-Organic Antioxidant, Ebselen, with Cyclodextrins in Aqueous Solution

Sunyong Kim, F. Hirayama, K. Uekama, 2002 .

Selective Crystallization of the Metastable Form IV Polymorph of Tolbutamide in the Presence of 2,6-Di-O-methyl-β-cyclodextrin in Aqueous Solution

W. Saenger, Y. Yamaguchi, F. Hirayama, 2006 .

Utilization of Diethyl-β-Cyclodextin as a Sustained-Release Carrier for Isosorbide Dinitrate

F. Hirayama, K. Abe, M. Ueno, 1988 .

Ethylated beta-cyclodextrins as hydrophobic drug carriers: sustained release of diltiazem in the rat.

F. Hirayama, K. Uekama, Y. Horiuchi, 1987, Journal of pharmaceutical sciences.

Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine.

F. Hirayama, K. Uekama, T. Irie, 1990, Chemical & pharmaceutical bulletin.

Complex formation of hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin with substituted benzenes in aqueous solution

K. Harata, F. Hirayama, K. Uekama, 1988 .

Chapter 40 – Improvement of Drug Properties by Cyclodextrins

F. Hirayama, K. Uekama, 2008 .

Improvement of Solubility and Oral Bioavailability of Rutin by Complexation with 2-Hydroxypropyl-β-cyclodextrin

F. Hirayama, K. Uekama, H. Arima, 2000, Pharmaceutical development and technology.

Enhancing effect of hydroxypropyl-beta-cyclodextrin on cutaneous penetration and activation of ethyl 4-biphenylyl acetate in hairless mouse skin.

F. Hirayama, K. Uekama, H. Arima, 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Design and in vitro evaluation of slow-release dosage form of piretanide: utility of beta-cyclodextrin:cellulose derivative combination as a modified-release drug carrier.

Y Horiuchi, F. Hirayama, K. Uekama, 1990, Journal of pharmaceutical sciences.

Some physicochemical properties of branched β-cyclodextrins and their inclusion characteristics

F. Hirayama, K. Uekama, Masanobu Yamamoto, 1989 .

Improving the aqueous stability of prostaglandin E2 and prostaglandin A2 by inclusion complexation with methylated-beta-cyclodextrins.

F. Hirayama, K. Uekama, M. Kurihara, 1984, Chemical & pharmaceutical bulletin.

Crystallization and polymorphic transition behavior of chloramphenicol palmitate in 2-hydroxypropyl-β-cyclodextrin matrix

F. Hirayama, K. Uekama, Fumitoshi Hirayama, 1996 .

Effects of Cyclodextrins on the Hydrolysis of Prostacyclin and Its Methyl Ester in Aqueous Solution

F. Hirayama, K. Uekama, M. Otagiri, 1981 .

Crystal structures of hexakis-(2,6-di-O-methyl)-cyclomaltohexaose (dimethyl-α-cyclodextrin) crystallized from acetone, and crystallized from hot water

W. Saenger, F. Hirayama, T. Steiner, 1996 .

Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.

T. Higashi, F. Hirayama, K. Uekama, 2008, Biomaterials.

Stabilizing and Solubilizing Effects of Sulfobutyl Ether β-Cyclodextrin on Prostaglandin E1 Analogue

M. Sudoh, F. Hirayama, K. Uekama, 2001, Pharmaceutical Research.

NMR spectroscopic characterization of metoprolol/cyclodextrin complexes in aqueous solution: cavity size dependency.

F. Hirayama, K. Uekama, H. Arima, 2004, Journal of pharmaceutical sciences.

Crystallization of a new polymorph of acetohexamide from 2-hydroxybutyl-β-cyclodextrin solution: form VI with a high aqueous solubility.

A. Altaf, F. Hirayama, K. Uekama, 2013, International journal of pharmaceutics.

Crystallization and polymorphic transitions of chlorpropamide in aqueous 2-hydroxybutyl-beta-cyclodextrin solution.

F. Hirayama, K. Uekama, H. Arima, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Preparation of amorphous indomethacin from aqueous 2,6-di-O-methyl-beta-cyclodextrin solution.

F. Hirayama, K. Uekama, H. Arima, 2008, International journal of pharmaceutics.

Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.

F. Hirayama, K. Uekama, H. Arima, 1999, Journal of pharmaceutical sciences.

Improvement of chemical instability of prostacyclin in aqueous solution by complexation with methylated cyclodextrins

F. Hirayama, K. Uekama, M. Kurihara, 1987 .

1H-NMR SPECTROSCOPIC EVIDENCE ON CHIRAL DISCRIMINATION OF dl-PIRPROFEN BY β-CYCLODEXTRIN COMPLEXATION

T. Imai, F. Hirayama, K. Uekama, 1985 .

Thermoresponsive Formation of Dimethyl Cyclodextrin Polypseudorotaxanes and Subsequent One-Pot Synthesis of Polyrotaxanes

Jun Li, Xia Song, Jingling Zhu, 2016 .

The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ‐cyclodextrin and its dissolution characteristics

F. Hirayama, K. Uekama, M. Anraku, 2016, The Journal of pharmacy and pharmacology.

Prominent inclusion effect of dimethyl-beta-cyclodextrin on photoisomerization of the thromboxane synthetase inhibitor (E)-4-(1-imidazoylmethyl)cinnamic acid.

K. Harata, F. Hirayama, T. Utsuki, 1992, Journal of pharmaceutical sciences.

Enhanced dissolution and oral bioavailability of α-tocopheryl esters by dimethyl-β-cyclodextrin complexation

F. Hirayama, K. Uekama, Y. Horiuchi, 1988 .

Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach.

F. Hirayama, K. Uekama, M. Otagiri, 2010, Journal of pharmaceutical sciences.

Enhanced bioavailability of a new thiazolidine derivative FPFS-410, an antidiabetic and lipid-lowering drug, after oral administration of its hydroxypropyl-beta-cyclodextrin complex to bile duct-cannulated rats.

F. Hirayama, K. Uekama, H. Arima, 2006, Journal of pharmaceutical sciences.

Inclusion complexation of p-hydroxybenzoic acid esters with 2-hydroxypropyl-beta-cyclodextrins. On changes in solubility and antimicrobial activity.

F. Hirayama, K. Uekama, T. Utsuki, 1993, Chemical & pharmaceutical bulletin.

Release control of fragrances by complexation with β-cyclodextrin and its derivatives

F. Hirayama, K. Uekama, H. Arima, 2018, Journal of Inclusion Phenomena and Macrocyclic Chemistry.

Characterization of itraconazole/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution.

F. Hirayama, K. Uekama, H. Arima, 1999, International journal of pharmaceutics.

Effect of Peracylation of β-Cyclodextrin on the Molecular Structure and on the Formation of Inclusion Complexes: An X-ray Study

G. Sheldrick, K. Harata, W. Saenger, 2001 .

Reduction of photohemolytic activity of benoxaprofen byβ-cyclodextrin complexations

F. Hirayama, K. Uekama, T. Irie, 1988 .

Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.

K. Motoyama, F. Hirayama, K. Uekama, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Slow-release system of pegylated lysozyme utilizing formation of polypseudorotaxanes with cyclodextrins.

T. Higashi, F. Hirayama, K. Uekama, 2009, International journal of pharmaceutics.

Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation.

T. Higashi, K. Motoyama, F. Hirayama, 2009, Chemical & pharmaceutical bulletin.

Inclusion Complexation of Prostaglandin F2α with γ-Cyclodextrin in Solution and Solid Phases

F. Hirayama, K. Uekama, M. Otagiri, 1984 .

Molecular dynamics of prostaglandin F2.ALPHA.-cyclodextrin complexes in aqueous solution.

H. Koinuma, F. Hirayama, K. Uekama, 1980 .

Inclusion complex of acetohexamide with beta-cyclodextrin and its hypoglycemic activity in rabbit.

F. Hirayama, K. Uekama, T. Yamaguchi, 1979, Chemical & pharmaceutical bulletin.

Utilization of cyclodextrin complexation for separation of E, A, and B prostaglandins by ion-exchange liquid chromatography.

F. Hirayama, K. Uekama, K. Ikeda, 1977, Journal of pharmaceutical sciences.

Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin.

F. Hirayama, K. Uekama, H. Arima, 2001, International journal of pharmaceutics.

In‐vivo and In‐vitro Correlation for Delayed‐release Behaviour of a Molsidomine/O‐carboxymethyl‐O‐ethyl‐β‐cyclodextrin Complex in Gastric Acidity‐controlled Dogs

F. Hirayama, K. Uekama, T. Horikawa, 1995, The Journal of pharmacy and pharmacology.

Improvement of pharmaceutical properties of insulin through conjugation with glucuronylglucosyl-β-cyclodextrin

T. Higashi, K. Motoyama, F. Hirayama, 2014, Journal of Inclusion Phenomena and Macrocyclic Chemistry.

Prednisolone‐appended α‐cyclodextrin: Alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6‐trinitrobenzenesulfonic acid‐induced colitis rats

F. Hirayama, K. Uekama, H. Arima, 2001 .

Preparation of prednisolone-appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior.

F. Hirayama, K. Uekama, H. Arima, 2001, Journal of pharmaceutical sciences.

Improvement of some pharmaceutical properties of nocloprost by β- and γ-Cyclodextrin Complexation

F. Hirayama, K. Uekama, M. Yamasaki, 1990 .

Improvement of dissolution characteristics and chemical stability of prostaglandin E1 by .GAMMA.-cyclodextrin complexation.

F. Hirayama, K. Uekama, M. Otagiri, 1984 .

Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation

F. Hirayama, K. Uekama, M. Otagiri, 1983 .

Improvement of thermal and photochemical stability of benzaldehyde by cyclodextrin complexation

F. Hirayama, K. Uekama, M. Otagiri, 1983 .

[Improvements of some pharmaceutical properties of aralkylalcohols by cyclodextrin complexation].

F. Hirayama, K. Uekama, M. Otagiri, 1982, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Effects of cyclodextrins on the acid hydrolysis of digoxin

F. Hirayama, K. Uekama, M. Otagiri, 1982, The Journal of pharmacy and pharmacology.

Inclusion Complexations of Indomethacin and Its Related Compounds with Cyclodextrins in Aqueous Solution

F. Hirayama, K. Uekama, M. Otagiri, 1982 .

[Enhanced bioavailability of acetohexamide by beta-cyclodextrin complexation (author's transl)].

F. Hirayama, K. Uekama, K. Arimori, 1980, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Cyclodextrin inclusion catalysis in the isomerization of prostglandin A1.

F. Hirayama, K. Uekama, 1979 .

PARTICIPATION OF CYCLODEXTRIN INCLUSION CATALYSIS IN PHOTOLYSIS OF CHLORPROMAZINE TO GIVE PROMAZINE IN AQUEOUS SOLUTION

F. Hirayama, K. Uekama, T. Irie, 1978 .

STRUCTUAL ELUCIDATION OF THE INCLUSION COMPLEXES OF TOLBUTAMIDE WITH α- AND β-CYCLODEXTRINS IN AQUEOUS SOLUTION

H. Koinuma, F. Hirayama, K. Uekama, 1978 .

THE NEW METHOD FOR DETERMINATION OF THE STABILITY CONSTANTS OF CYCLODEXTRIN–PROSTAGLANDIN INCLUSION COMPLEXES BY LIQUID CHROMATOGRAPHY

F. Hirayama, K. Uekama, T. Irie, 1978 .

Controlled release of a water-soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives.

F. Hirayama, K. Uekama, H. Arima, 2000, Journal of controlled release : official journal of the Controlled Release Society.

Analysis of the phase solubility diagram of a phenacetin/competitor/beta-cyclodextrin ternary system, involving competitive inclusion complexation.

F. Hirayama, K. Uekama, H. Arima, 2001, Chemical & pharmaceutical bulletin.

Micellar Effects on Base-Catalyzed Isomerization of Prostaglandin A1 and Prostaglandin A2

F. Hirayama, K. Uekama, S. Yamasaki, 1978 .

Solid-State 13C Nuclear Magnetic Resonance Spectroscopic Study on Amorphous Solid Complexes of Tolbutamide with 2-Hydroxypropyl-α-and -β-Cyclodextrins

Hidetoshi Arima, F. Hirayama, K. Uekama, 1999, Pharmaceutical Research.

Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability

Osama A. Soliman, F. Hirayama, K. Uekama, 1997 .

Effects of Hydrophilic Cyclodextrins on Aggregation of Recombinant Human Growth Hormone

S. Tajiri, F. Hirayama, K. Uekama, 2004, Pharmaceutical Research.

The circular dichroism spectra of the β-cyclodextrin complex with 2-hydroxytropone

F. Hirayama, K. Uekama, H. Yamaguchi, 1978 .

CRYSTAL STRUCTURES OF PERMETHYLATED α-CYCLODEXTRIN COMPLEXES WITH L- AND D-MANDELIC ACIDS

K. Harata, F. Hirayama, K. Uekama, 1983 .

6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl-β-cyclodextrin: solubilizing ability and some cellular effects

F. Hirayama, K. Uekama, H. Arima, 2002 .

Improved stability of Opalmon tablets under humid conditions IV: effect of polysaccharides and disintegrants on the stability and dissolution property of Opalmon tablets.

F. Hirayama, K. Uekama, H. Arima, 2008, Chemical & pharmaceutical bulletin.

Contribution of Cholesterol and Phospholipids to Inhibitory Effect of Dimethyl-β-Cyclodextrin on Efflux Function of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 in Vinblastine-Resistant Caco-2 Cell Monolayers

Hidetoshi Arima, F. Hirayama, K. Uekama, 2004, Pharmaceutical Research.

Inclusion complexes of cyclodextrins with cinnamic acid derivatives: Dissolution and thermal behavior.

F. Hirayama, K. Uekama, M. Inoue, 1979 .

Potential Use of 2-Hydroxypropyl-β-cyclodextrin for Preparation of Orally Disintegrating Tablets Containing dl -α-Tocopheryl Acetate, an Oily Drug

K. Motoyama, F. Hirayama, K. Uekama, 2009 .

Potential use of 2-hydroxypropyl-beta-cyclodextrin for preparation of orally disintegrating tablets containing dl-alpha-tocopheryl acetate, an oily drug.

K. Motoyama, F. Hirayama, K. Uekama, 2009, Chemical & pharmaceutical bulletin.

Enhanced Bioavailability of Digitalis Glycoside by Cyclodextrin Complexation

F. Hirayama, K. Uekama, M. Otagiri, 1982 .

In Vitro and In Vivo Evaluation of Hydrophilic C60(OH)10/2-Hydroxypropyl-β-cyclodextrin Nanoparticles as an Antioxidant.

F. Hirayama, K. Uekama, M. Anraku, 2016, Journal of pharmaceutical sciences.

In vitro and in situ models for the prediction of in vivo absorption behavior of sulfonamides following dissolution.

F. Hirayama, K. Uekama, M. Otagiri, 1983, Chemical & pharmaceutical bulletin.

[Model analyses of interfacial transfer and absorption behaviors of drugs following dissolution: approach to evaluation procedure of bioavailability (author's transl)].

F. Hirayama, K. Uekama, J. Fujisaki, 1980, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

In vitro transdermal permeation behavior of isosorbide dinitrate in the absence and presence of 2-hydroxypropyl-β-cyclodextrin: solutions and suspensions

F. Hirayama, K. Uekama, T. Irie, 2019, Journal of Inclusion Phenomena and Macrocyclic Chemistry.

Inclusion Complex Formation of Captopril with α‐ and β‐Cyclodextrins in Aqueous Solution: NMR Spectroscopic and Molecular Dynamic Studies

F. Hirayama, K. Uekama, H. Arima, 2002 .

Improvement of chemical instability of digitoxin in aqueous solution by complexation with beta-cyclodextrin derivatives.

F. Hirayama, K. Uekama, F Hirayama, 1988, Chemical & pharmaceutical bulletin.

Involvement of cholesterol in the inhibitory effect of dimethyl‐β‐cyclodextrin on P‐glycoprotein and MRP2 function in Caco‐2 cells

Hidetoshi Arima, F. Hirayama, K. Uekama, 2003, FEBS letters.

Improvement of chemical instability of carmoful in beta-cyclodextrin solid complex by utilizing some organic acids.

F. Hirayama, K. Uekama, M. Kikuchi, 1987, Chemical & pharmaceutical bulletin.

Improvement of some pharmaceutical properties of carmoful by cycrodextrin complexation

F. Hirayama, K. Uekama, M. Otagiri, 1984 .

Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.

T. Imai, F. Hirayama, K. Uekama, 2000, Chemical & pharmaceutical bulletin.

Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.

F. Hirayama, K. Uekama, H. Arima, 2001, Journal of pharmaceutical sciences.

Inhibitory Effect of 2‐Hydroxypropyl‐β‐cyclodextrin on Crystal‐growth of Nifedipine During Storage: Superior Dissolution and Oral Bioavailability Compared with Polyvinylpyrrolidone K‐30

F. Hirayama, K. Uekama, Y. Horiuchi, 1992, The Journal of pharmacy and pharmacology.

Studies on the antitumor bisabolane sesquiterpenoids isolated from Curcuma xanthorrhiza.

F. Hirayama, H. Itokawa, K. Takeya, 1985, Chemical & pharmaceutical bulletin.

Characterization of Itraconazole / 2-Hydroxypropyl-ß-Cyclodextrin Inclusion Complex in Aqueous Solution

A. Kondo, F. Hirayama, K. Uekama, 1999 .

Slow-release of famotidine from tablets consisting of chitosan/sulfobutyl ether β-cyclodextrin composites.

F. Hirayama, K. Uekama, M. Anraku, 2015, International journal of pharmaceutics.

Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.

F. Hirayama, K. Uekama, H. Arima, 2001, The Journal of pharmacology and experimental therapeutics.

Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.

F. Hirayama, K. Uekama, M. Otagiri, 2010, International journal of pharmaceutics.

Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota.

K. Azuma, S. Ifuku, F. Hirayama, 2020, International journal of biological macromolecules.

Partition behavior and ion pair formation of some prostaglandins.

F. Hirayama, K. Uekama, Harumi Tanaka, 1978 .

Glucose Responsive Rheological Change and Drug Release from a Novel Worm-like Micelle Gel Formed in Cetyltrimethylammonium Bromide/Phenylboronic Acid/Water System.

F. Hirayama, K. Uekama, Yuya Egawa, 2018, Molecular pharmaceutics.

In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C

K. Higaki, T. Higashi, K. Motoyama, 2019, International journal of molecular sciences.

Study of the inclusion complexes formed between 4-phenylbutyrate and α-, β- and γ-cyclodextrin in solution and evaluation on their taste-masking properties.

F. Hirayama, M. Otagiri, Kenji Tsukigawa, 2022, The Journal of pharmacy and pharmacology.

Reduction of bitterness of antihistaminic drugs by complexation with β-cyclodextrins.

Keiichi Motoyama, Hidetoshi Arima, Satoshi Tsuruta, 2011, Journal of pharmaceutical sciences.

Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats.

F. Hirayama, K. Uekama, H. Arima, 1999, Biological & pharmaceutical bulletin.

Stabilizing effect of β-cyclodextrin on Limaprost, a PGE₁ derivative, in Limaprost alfadex tablets (Opalmon) in highly humid conditions.

Y. Inoue, F. Hirayama, K. Uekama, 2014, Chemical & pharmaceutical bulletin.

Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.

F. Hirayama, K. Uekama, H. Arima, 2007, Chemical & pharmaceutical bulletin.

The preparation and validation of chitosan tablets that rapidly disperse and disintegrate as an oral adsorbent in the treatment of lifestyle-related diseases.

F. Hirayama, M. Otagiri, M. Anraku, 2021, Carbohydrate polymers.

Formation of Elastic Gels from Deacetylated Chitin Nanofibers Reinforced with Sulfobutyl Ether β-Cyclodextrin

S. Ifuku, F. Hirayama, K. Uekama, 2015 .

Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats.

T. Anno, K. Motoyama, F. Hirayama, 2011, International journal of pharmaceutics.

Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats.

K. Azuma, T. Higashi, K. Motoyama, 2021, Life sciences.

In vitro and in vivo gene delivery mediated by Lactosylated dendrimer/alpha-cyclodextrin conjugates (G2) into hepatocytes.

Keiichi Motoyama, Yukio Ando, Hidetoshi Arima, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor.

F. Hirayama, K. Uekama, H. Arima, 2006, Journal of pharmaceutical sciences.

Preparation and antioxidant activity of PEGylated chitosans with different particle sizes.

F. Hirayama, K. Uekama, M. Otagiri, 2014, International journal of biological macromolecules.

In vitro and in vivo evaluation of delayed-release behavior of diltiazem from its O-carboxymethyl-O-ethyl-β-cyclodextrin complex

F. Hirayama, K. Uekama, Y. Horiuchi, 1993 .

An oral absorbent, surface-deacetylated chitin nano-fiber ameliorates renal injury and oxidative stress in 5/6 nephrectomized rats.

S. Ifuku, F. Hirayama, K. Uekama, 2017, Carbohydrate polymers.

Antioxidant and renoprotective activity of chitosan in nephrectomized rats.

D. Tsuchiya, F. Hirayama, K. Uekama, 2012, Carbohydrate polymers.

Preparation and evaluation of freeze dried surface-deacetylated chitin nanofiber/sacran pellets for use as an extended-release excipient.

K. Azuma, S. Ifuku, F. Hirayama, 2019, International journal of biological macromolecules.

Sacran, a High-molecular Weight Polysaccharide Inhibits Renal Injury and Oxidative Stress in Chronic Renal Failure Model Rats

T. Higashi, K. Motoyama, F. Hirayama, 2018, Journal of Nutritional Biology.

Improvement of Subcutaneous Bioavailability of Insulin by Sulphobutyl Ether β‐Cyclodextrin in Rats

S. Tajiri, F. Hirayama, K. Uekama, 2000, The Journal of pharmacy and pharmacology.

Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats

T. Anno, T. Higashi, K. Motoyama, 2011, Journal of drug delivery.

Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex.

F. Hirayama, K. Uekama, H. Arima, 2000, Chemical & pharmaceutical bulletin.

Mechanisms of deceleration by methylated cyclodextrins in the dehydration of prostaglandin E2 and the isomerization of prostaglandin A2 in aqueous solution.

F. Hirayama, K. Uekama, M. Kurihara, 1986, Chemical & pharmaceutical bulletin.

Effect of 2-Hydroxypropyl-β-cyclodextrin on Release Rate of Metoprolol from Ternary Metoprolol/2-hydroxypropyl-β-cyclodextrin/Ethylcellulose Tablets

F. Hirayama, K. Uekama, H. Arima, 2002 .

Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA.

F. Hirayama, K. Uekama, H. Arima, 2008, Journal of pharmaceutical sciences.

Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates

Hidetoshi Arima, F. Hirayama, K. Uekama, 2005 .

Preparation of Hydrophilic Nanoparticles of C60 with High Resistance to Aggregation during Storage, using 2-Hydroxypropyl-β-cyclodextrin

F. Hirayama, K. Uekama, H. Aoshima, 2009 .

Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation.

F. Hirayama, K. Uekama, M. Yamamoto, 1992, Chemical & pharmaceutical bulletin.

Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment.

F. Hirayama, K. Uekama, H. Arima, 1996, Chemical & pharmaceutical bulletin.

Some Pharmaceutical Properties of a New Branched Cyclodextrin, 6-O-α-(4-O- α-D-Glucuronyl)-D-glucosylβ-cyclodextrin

F. Hirayama, K. Uekama, H. Arima, 2002 .

A Comparison of the Phosphorus Content in Prescription Medications for Hemodialysis Patients in Japan.

F. Hirayama, M. Otagiri, T. Maruyama, 2017, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Biomaterials based on freeze dried surface-deacetylated chitin nanofibers reinforced with sulfobutyl ether β-cyclodextrin gel in wound dressing applications.

K. Azuma, S. Ifuku, F. Hirayama, 2016, International journal of pharmaceutics.

[Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers].

F. Hirayama, 1993, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression.

T. Higashi, K. Motoyama, F. Hirayama, 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Polypseudorotaxanes of pegylated insulin with cyclodextrins: application to sustained release system.

T. Higashi, F. Hirayama, K. Uekama, 2007, Bioorganic & medicinal chemistry letters.

Combined use of cyclodextrins and hydroxypropylmethylcellulose stearoxy ether (Sangelose®) for the preparation of orally disintegrating tablets of type-2 antidiabetes agent glimepiride

F. Hirayama, H. Aldawsari, M. Okubo, 2014, Journal of Inclusion Phenomena and Macrocyclic Chemistry.

In‐vivo and in‐vitro evaluations of a modified‐release oral dosage form of nifedipine by hybridization of hydroxypropyl‐β‐cyclodextrin and hydroxypropylcelluloses in dogs

F. Hirayama, K. Uekama, Zheng Wang, 1994, The Journal of pharmacy and pharmacology.

Cyclodextrin-based controlled drug release system.

F. Hirayama, K. Uekama, Uekama, 1999, Advanced drug delivery reviews.

Release Characteristics of Nifedipine from 2-Hydroxypropyl-β-cyclodextrin Complex during Storage and Its Modification of Hybridizing Polyvinylpyrrolidone K-30

F. Hirayama, K. Uekama, Zheng Wang, 1993 .

Formation of the ternary inclusion complex of limaprost with α- and β-cyclodextrins in aqueous solution.

Y. Inoue, F. Hirayama, K. Uekama, 2015, Chemical & pharmaceutical bulletin.

Mass Spectroscopic Evidence on Inhibiting Effect of Maltosyl–β‐Cyclodextrin on Insulin Self‐association

F. Hirayama, K. Uekama, T. Irie, 1996 .

Potential Use of Folate-polyethylene glycol (PEG)-Appended Dendrimer (G3) Conjugate with alpha-Cyclodextrin as DNA Carriers to Tumor Cells

T. Higashi, K. Motoyama, F. Hirayama, 2011, Nature Precedings.

K. Motoyama, F. Hirayama, K. Uekama, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The Effects of Sacran, a Sulfated Polysaccharide, on Gut Microbiota Using Chronic Kidney Disease Model Rats.

Panayiotis D. Megaloikonomos, K. Azuma, T. Higashi, 2022, Biological & pharmaceutical bulletin.